FFAR1 and type 2 diabetes mellitus: In conclusion, although the GPR40 antagonist, DC260126 might not be used for the treatment of type 2 diabetes, our data provided evidences that the theory under GPR40 antagonism for the treatment of type 2 diabetes might be reasonable in the early stage of type 2 diabetes.